CDSCO Panel Approves Eli Lilly's Protocol Amendment proposal to study Antidiabetic Drug Tirzepatide

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-08-04 12:15 GMT | Update On 2024-08-04 12:15 GMT

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has approved the protocol amendment proposal presented by drug major Eli Lilly to study the antidiabetic drug Tirzepatide.

This came after drug maker Eli Lilly presented protocol amendment (b) dated 24 April 2024 protocol no. I8F-MC-GPIJ.

Tirzepatide is in a class of medications called glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonists.

Tirzepatide activation of GIP receptors augments insulin sensitivity and secretion and thereby helps reinforce the mechanisms regulating blood glucose levels.Tirzepatide activation of GIP receptors augments insulin sensitivity and secretion and thereby helps reinforce the mechanisms regulating blood glucose levels.

Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclinical and clinical trials.

At the recent SEC meeting for Endocrinology and Metabolism held on July 11, 2024, the expert panel reviewed the proposal presented by the drug major Eli Lilly for the protocol amendment (b) dated 24 April 2024 protocol no. I8F- MC-GPIJ.

After detailed deliberation, the committee recommended the approval of the protocol amendment as presented by the firm.

Also Read: Zydus Life Sciences Gets CDSCO Panel Nod to Study anti-cancer drug Relugolix

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

CDSCO Panel Approves Eli Lilly's Protocol Amendment proposal to study Antidiabetic Drug Tirzepatide

Similar News

Dr Reddy's Labs API Mirfield facility gets 7 USFDA observations

CDSCO Panel Rejects Theon Pharma's Proposal for Empagliflozin, Linagliptin, Metformin FDC

Virchow Biotech Gets CDSCO Panel Nod for Semaglutide BE, Phase III Trials

Industry needs to come forward, take advantage of funds available for MedTech Sector: DoP Joint Secretary

USFDA inspection: Aurobindo Pharma receives 8 observations for Unit-XII

USFDA issues 4 observations for Zydus Jarod injectable manufacturing plant

Lupin gets 2 USFDA observations for Aurangabad facility

Tamil Nadu Pharma Firms Under ED Lens for Suspected Financial Irregularities